Gene Silencing Therapies for Huntington’s Disease
Huntington’s disease (HD) is a rare, autosomal‑dominant neurodegenerative disorder precipitated by a pathological expansion of CAG trinucleotide repeats in exon 1 of the huntingtin (HTT) gene. Mutant huntingtin (mHTT) imposes a toxic gain‑of‑function that progressively compromises neuronal circuitry...
Saved in:
| Main Authors: | Chunlan Hao, Hanfeng Ji |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Iran University of Medical Sciences
2025-05-01
|
| Series: | Neurology Letters |
| Subjects: | |
| Online Access: | https://www.neurologyletters.com/article_220437_bd85211e84319a406a0d5d56fd626a43.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of an Antisense Oligonucleotide Targeting CAG Repeats: A Patient-Customized Therapy Study for Huntington’s Disease
by: Sergio Adrian Ocampo-Ortega, et al.
Published: (2024-12-01) -
Prospects of etiopathogenetic treatment of Huntington’s disease
by: O. B. Kondakova, et al.
Published: (2023-03-01) -
Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease
by: Jocelynn R. Pearl, et al.
Published: (2025-05-01) -
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification
by: Rachel J. Harding, et al.
Published: (2025-04-01) -
The RNA revolution in medicine: from gene regulation to clinical therapeutics
by: Jiwon Jeong, et al.
Published: (2025-12-01)